Dr. Luke on the Clinical Trial Landscape for Melanoma

Jason Luke, MD
Published Online: Tuesday, Nov 28, 2017



Jason Luke, MD, assistant professor of medicine at the University of Chicago Medicine, discusses the clinical trial landscape for melanoma.

According to Luke, the clinical trial landscape is split in 2 areas of focus. Registrational phase III trials are looking at more robust combinations that could impact the field right away. And then there is the developmental space, which is investigating what molecules are going to be the next generation of things to look for.

There is preliminary data inhibiting a molecule called LAG3, which is a T cell checkpoint that could rescue patients who have become refractory to PD-1 blockade.
 


Jason Luke, MD, assistant professor of medicine at the University of Chicago Medicine, discusses the clinical trial landscape for melanoma.

According to Luke, the clinical trial landscape is split in 2 areas of focus. Registrational phase III trials are looking at more robust combinations that could impact the field right away. And then there is the developmental space, which is investigating what molecules are going to be the next generation of things to look for.

There is preliminary data inhibiting a molecule called LAG3, which is a T cell checkpoint that could rescue patients who have become refractory to PD-1 blockade.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: 13th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 28, 20182.0
Publication Bottom Border
Border Publication
x